Seeking Alpha

XOMA Corp. (XOMA +1.8%) trades up after saying it's selected active non-infectious anterior...

XOMA Corp. (XOMA +1.8%) trades up after saying it's selected active non-infectious anterior scleritis, the inflammation of the fibrous white membrane surrounding the eyeball excluding the cornea, as the third indication in it's proof-of-concept program for gevokizumab. The company will work with the National Eye Institute on designing the study protocol.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)